Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group

Iriyama, Noriyoshi; Tokuhira, Michihide; Takaku, Tomoiku; Sato, Eriko; Ishikawa, Masatoshi; Nakazato, Tomonori; Sugimoto, Kei; Fujita, Hiroyuki; Fujioka, Isao; Hatta, Yoshihiro; Kizaki, Masahiro; Komatsu, Norio; Asou, Norio; Kawaguchi, Tatsuya

doi:10.1016/j.leukres.2017.01.003

Cited by 13 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 However, prior to TKI era, the treatment responses were shown to be generally similar in both cases with TR-CML and de novo CML. 4,6 Similarly, in the TKI era, response to TKI treatment is excellent in patients with TR-CML in chronic phase. 6,11 Iriyama et al 6 have investigated the prognosis of 297 de novo CML and 11 TR-CML patients with a median follow-up of 48 months.…”

Section: Discussionmentioning

confidence: 99%

“…4 On the other hand, therapy-related CML (TR-CML) is a relatively rare entity, and approximately, 150 cases of TR-CML or CML as a secondary malignancy have been reported in the literature. [4][5][6][7] TR-L can be associated with certain karyotypes such as abnormalities of chromosomes 5 and/or 7 or a complex karyotype. 5 On the contrary, isolated t(9;22) (q34;q11) abnormalities occur in TR-CML, and additional cytogenetic abnormalities are not usually observed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

et al. 2020

View full text Add to dashboard Cite

Background: Therapy-related leukemia is a well-recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims: Hematologic toxicities including late-onset myeloid neoplasms have been reported after PRRT; however, therapy-related chronic myeloid leukemia (TR-CML) following PRRT is a relatively rare entity. Methods: We present a 64-year-old male who received PRRT for pancreas neuroendocrine tumor and then developed TR-CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy. Results: Patients with TR-CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases. Conclusions: The physicians should be aware of the short-and long-term hematologic toxicities of PRRT including TR-CML, and careful monitoring is mandatory in this group of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

et al. 2020

View full text Add to dashboard Cite

show abstract

“…2 Recently, the Japanese CML Cooperative Study Group compiled a list of 11 cases of CML subsequent to chemtherapy and/or radiotherapy for different solid cancers. 3 This list includes two patients who developed CML two and five years after radiotherapy, which was the sole teratment for prostate cancer and pharyngeal cancer, respectively. Similarly, a survey on three cohorts (thyroid, prostate, and uterine corpus cancer survivors) initially treated by radiotherapy demonstrated that they had an increased risk of myeloid neoplasms, including CML.…”

mentioning

confidence: 99%

“…4 Considering the previous radiotherapy for prostate cancer, our patient likely developed radiotherapyrelated CML. Although a significant number of secondary CML cases have been reported to be associated with preceding chemotherapy, 3,5 radiotherapy-related CML may be rare. In addition to therapeutic radiation, diagnostic radiation may increase the risk of CML when used repeatedly in the same individual.…”

mentioning

confidence: 99%

“…Recent studies reported that patients with therapy-related CML exhibited a good therapeutic response to tyrosine kinase inhibitors and favorable outcomes similar to de novo CML. 3,5,8 However, these studies comprised patients who were treated by chemotherapy alone, chemotherapy with radiotherapy, or immunosuppressive therapy for previous diseases. Thus, further case accumulation of radiation-related CML and long-term prospective epidemiologic studies are needed to define this peculiar condition as a distinct clinical entity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Is There an Entity of Radiation-Induced Chronic Myeloid Leukemia? Report of a Case and Brief Review of the Literature

Miyoshi¹,

Mori

Yamasaki

et al. 2020

JCEH

View full text Add to dashboard Cite

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

et al. 2018

View full text Add to dashboard Cite

ABL1-tyrosine kinase inhibitors (TKIs) have led to dramatic changes in treatment strategies for chronic myeloid leukemia in the chronic phase (CML-CP). However, clinical studies have highlighted increasing numbers of adverse events (AE) with TKIs. Although TKI modification plays a key role in AE management, this process is poorly understood, particularly in terms of the TKI nilotinib. In the present study, we retrospectively analyzed the records of 70 patients with newly diagnosed (ND)-CML-CP who were treated with nilotinib to investigate the drug potency of nilotinib and treatment management. During a median observation period of 3.4 years, 76% of patients continued nilotinib as a first-line treatment. The 1-year and overall major molecular response (MMR) rates and the overall molecular response (MR) 4.5 rate for all patients receiving first-line nilotinib therapy were 70, 84.2, and 50%, respectively. No case progressed to the accelerated or blast phase during the study. To avoid AEs during the early phase, nilotinib doses were reduced to < 600 mg/day in a third of patients (Reduced group); these patients experienced better therapeutic efficacy and a lower rate of AEs relative to those in Standard group (300 mg twice daily). Ten patients who received < 600 mg/day of nilotinib throughout the study had a 1-year MMR rate and overall MR4.5 rate of 90 and 60%, respectively. In summary, our findings indicate that careful management, including dose reduction, can yield better outcomes in patients with ND-CML-CP.

show abstract

Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group

Cited by 13 publications

References 22 publications

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Is There an Entity of Radiation-Induced Chronic Myeloid Leukemia? Report of a Case and Brief Review of the Literature

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

Contact Info

Product

Resources

About